Graphite Bio Investor Relations Material
Latest events
M&A Announcement
Graphite Bio
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Graphite Bio Inc
Access all reports
Graphite Bio Inc is a biotechnology company engaged in the development of gene editing therapies for the treatment of serious genetic diseases. Its research focuses on employing precise DNA repair mechanisms to create targeted and durable treatments. The company primarily serves the healthcare and pharmaceutical sectors. Graphite Bio Inc is headquartered in South San Francisco, California, and its shares are listed on the NASDAQ.
Latest articles
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
Ticker symbol
GRPH
Country
🇺🇸 United States